KRAS and cancer: This peptide exhibited submicromolar affinity for K-Ras, demonstrating its potential to disrupt the critical interaction between K-Ras and its effector proteins, including Raf, Ral-GDS, and Tiam1 [33], which could significantly affect cancer cells.